XORTX Therapeutics Inc.
XORTX Therapeutics Inc.
XORTX Therapeutics Inc. is a biopharmaceutical company with three clinically advanced products in development – XRx-008 for Autosomal Dominant Polycystic Kidney Disease (ADPKD), XRx-101 for Coronavirus / COVID-19 infection in addition to ongoing in licensing activity relating to potential therapies for Type 2 Diabetic Nephropathy (T2DN). The Company has strong intellectual property rights and established proof of concept through independent clinical studies. XORTX is working to advance its clinical development stage products that target xanthine oxidase to inhibit production of uric acid. At XORTX Therapeutics, we are dedicated to developing medications to improve the quality of life and future of patients.
XORTX Therapeutics Inc. (XRX)
SEDAR Information
Company Info
Capitalization
Company Officers
Bulletins
2018-0111 – Fundamental Change – APAC Resources Inc./XORTX Therapeutics Inc.
Le 10 janvier/January 2018
XORTX Therapeutics Inc., the issuer resulting from a Fundamental Change of APAC Resources Inc. has been approved for listing.
Advertisement
Publicité
